Member Contact: Ben Kiefel
Position: Chief Operating Officer
Industry: Biotech & Pharmaceuticals
affinity bio was established in 2009 to develop an industry-beating, ultra-rapid antibody display platform, and has labs in the Small Technologies Cluster in Scoresby, Victoria.
Retained Display (ReD) is our proprietary, ultra-rapid antibody display platform. ReD delivers highly-soluble single chain antibodies from our diverse library within 5 days. The system generates sequence diverse, first-round antibodies of nanomolar affinities against antigens ranging from small peptides through to large proteins. Our highly-soluble scaffold is primed during the screening process for high-level expression in bacterial systems and ReD output is suitable for rapid conversion into Fab and bi-specific formats.
ReD is adaptable for other protein evolution projects including non-antibody scaffolds, enzymes, peptides and industrial proteins.
affinity bio is the recipient of grants under the Commercialisation Australia program which is currently supporting exemplification of ReD against collaborative targets.